On October 5, the Ministry of Health of the Russian Federation canceled the state registration of six medicines and excluded them from the State Register of Medicines (GRLS). These include:
– “Avaxim 160 (vaccine for the prevention of hepatitis A, inactivated, adsorbed)” (vaccine for the prevention of viral hepatitis A), suspension for intramuscular administration, 0.5 ml dose, manufactured by Sanofi Pasteur S.A. (France). MIBP vaccine.
– “Geloplasma balance” (gelatin), solution for infusion, 3%, produced by Fresenius Kabi France (France). A plasma replacement agent.
– “NewPro®” (rotigotin), transdermal patch 2 mg/24 h, 4 mg/24 h, 6 mg/24 h, 8 mg/24 h, manufactured by UCB Manufacturing Ireland Ltd. (Ireland). Antiparkinsonian agent, dopamine receptor agonist.
– “Propofol Fresenius” (propofol), an emulsion for intravenous administration of 10 mg/ml, produced by Fresenius Kabi Austria GmbH (Austria). Non-inhalation general anesthesia agent.
– “Ceftazidime Kabi” (ceftazidime), powder for preparation of solution for infusions, 2000 mg, produced by Labesfal Laboratories Almiro S.A. (Portugal). Cephalosporin (antibiotic).
– “Ceftazidime Kabi” (ceftazidime), powder for the preparation of a solution for intravenous and intramuscular administration, 500 mg, 1000 mg, produced by Labesfal Laboratories Almiro S.A. (Portugal). Cephalosporin (antibiotic).
The basis was the submission of applications by authorized persons.
The day before, the Ministry of Health suspended the use of 20 medicines with ranitidine and canceled the state registration of three drugs.
